Post-Imatinib Progression: Decision Factors and Treatment Options

EP: 1.Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy

EP: 2.Biological Mechanisms of GIST Resistance and Tumor Heterogeneity

EP: 3.Monitoring Tumor Heterogeneity and Detecting Resistance

Now Viewing

EP: 4.Post-Imatinib Progression: Decision Factors and Treatment Options

EP: 5.INVICTUS Trial: Ripretinib in Fourth-Line Setting

EP: 6.INTRIGUE Trial: Key Findings in Second-Line Setting

EP: 7.ctDNA Biomarkers in INTRIGUE: Understanding Resistance Patterns

EP: 8.Managing Adverse Events With Different TKIs

EP: 9.Next-Generation Treatment Strategies for GIST: Evaluating Combination Therapies and Mutation-Specific Approaches

EP: 10.Practical Recommendations for Community Oncologists

Video content above is prompted by the following:

• With imatinib as our established first-line therapy for advanced GIST, what key factors influence your decision-making when patients progress? What are our standard second-line options, and what factors influence this treatment selection?
• What specific clinical or molecular factors would lead you to consider increasing imatinib dosing rather than switching to a different TKI?
• What specific clinical or radiographic patterns at the time of progression signal would definitively guide you to switch therapies vs dose escalation?